NCT07048158

Brief Summary

Noncommunicable diseases (NCDs) such as type 2 diabetes (T2D) and cardiovascular disease (CVD) account for more deaths globally than any other condition. In 2018, the WHO reported that NCDs accounted for 71% of global deaths. They also showed that low- and middle-income countries are disproportionately affected by NCDs, accounting for 85% of NCD-related deaths among individuals aged 30-69 y. Among NCDs, CVD is the leading and fourth-leading causes of death, accounting for 19.5 million deaths worldwide in 2018. Furthermore, despite increasing global awareness, the prevalence of these conditions continues to increase at alarming rates. Deaths from CVD are expected to reach 23.6 million annually by 2030 from 17.6 million deaths in 2016. The underlying aetiology of these conditions is complex, as they can be influenced by several environmental, genetic, and behavioural factors. However, diet and nutrition play a particularly important role in these conditions, especially in the context of the double burden of malnutrition facing many low- and middle-income countries.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for not_applicable cardiovascular-diseases

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable cardiovascular-diseases

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 24, 2025

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 2, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

July 8, 2025

Status Verified

July 1, 2025

Enrollment Period

3 months

First QC Date

June 24, 2025

Last Update Submit

July 2, 2025

Conditions

Keywords

Complementary and alternative medicineHerbal Medicine

Outcome Measures

Primary Outcomes (4)

  • Lipid profile

    Total cholesterol levels, Triglycerides levels, LDL- cholesterol levels, HDL-cholesterol levels

    Week 0, 4, 8 and 12

  • Cardiac inflammatory levels

    C-reactive protein

    Week 0, 4, 8 and 12

  • Cardiac injury levels

    Creatine kinase

    Week 0, 4, 8 and 12

  • Cardiac remodelling status

    Matrix metalloproteinases-9 (MMP-9)

    Week 0, 4, 8 and 12

Secondary Outcomes (2)

  • Quality of Life of subject

    Week 0, 4, 8 and 12

  • Self-perceived health status

    Week 0, 4, 8 and 12

Study Arms (1)

Perfect Heartion Drink Interventional Arm

EXPERIMENTAL

Subjects will be required to consume PH drink for 12 weeks, at the dosage of 15g twice daily. Compliance form will be given to monitor the compliance of subject.

Dietary Supplement: Perfect Heartio Drink

Interventions

Perfect Heartio DrinkDIETARY_SUPPLEMENT

Perfect Heartio (PH) drink is a nutritional drink composed of diluted herbal extracts of TCM, including ginger, Glycyrrhiza uralensis, Alternanthera sessilis, Panax notoginseng, Red date, Codonopsis pilosula, Ligusticum chuanxiong, Astragalus membranaceus.

Perfect Heartion Drink Interventional Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • General healthy subjects during enrolment
  • Age 18 and above
  • Willing to comply with interventional plan and comes to do follow up
  • Willing to gives consent

You may not qualify if:

  • Use nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week during enrolment
  • Use of anticoagulants or corticosteroids
  • Use of individual supplements of vitamin A, E, or beta carotene more than once a week during enrolment
  • Renal failure or dialysis, cirrhosis, other serious conditions that precluded participation
  • No previous history of cancer (except nonmelanoma skin cancer)
  • Pregnant or lactating woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCSI University

Cheras, Kuala Lumpur, 56000, Malaysia

RECRUITING

Related Publications (2)

  • Cooper F. How to publish a winning newsletter. Health Care Can. 1979 Sep;21(9):41-2. No abstract available.

    PMID: 10243891BACKGROUND
  • Ling Lee W, Chinna K, Sumintono B. Psychometrics assessment of HeartQoL questionnaire: A Rasch analysis. Eur J Prev Cardiol. 2021 Oct 13;28(12):e1-e5. doi: 10.1177/2047487320902322. Epub 2020 Feb 4. No abstract available.

    PMID: 34647582BACKGROUND

MeSH Terms

Conditions

Cardiovascular DiseasesLipid Metabolism Disorders

Condition Hierarchy (Ancestors)

Metabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Chung Keat Tan, PhD

    UCSI University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chung Keat Tan, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Model Details: Subjects will be required to consume Perfect Heartio (PH) drink for 12 weeks, at the dosage of 15g twice daily. Compliance form will be given to monitor the compliance of subject. Assessment will be conducted at week 0, 4, 8 and 12. Perfect Heartio (PH) is a nutritional drink composed of mainly diluted herbal extracts of TCM, including ginger, Glycyrrhiza uralensis, Alternanthera sessilis, Panax notoginseng, Red date, Codonopsis pilosula, Ligusticum chuanxiong, Astragalus membranaceus.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2025

First Posted

July 2, 2025

Study Start

April 1, 2025

Primary Completion

June 30, 2025

Study Completion

December 31, 2025

Last Updated

July 8, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. All of the individual participant data collected during the trial, after de-identification will be shared upon reasonable request. Additional documents including study protocol, statistical analysis plan, informed consent form and clinical study report will also be made available. The data will be available immediately following publication with no end date. Data will be shared with anyone who wishes to access with reasonable request. The data can be used for any types of analyses.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Upon publication of the study outcomes, for a time frame of 5 years
Access Criteria
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. All of the individual participant data collected during the trial, after de-identification will be shared upon reasonable request. Additional documents including study protocol, statistical analysis plan, informed consent form and clinical study report will also be made available. The data will be available immediately following publication with no end date. Data will be shared with anyone who wishes to access with reasonable request. The data can be used for any types of analyses.

Locations